AJR ARRS Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quaia, E.
Right arrow Articles by Cova, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quaia, E.
Right arrow Articles by Cova, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
DOI:10.2214/AJR.05.0527
AJR 2006; 186:1560-1570
© American Roentgen Ray Society


Original Research

Comparison of Visual and Quantitative Analysis for Characterization of Insonated Liver Tumors After Microbubble Contrast Injection

Emilio Quaia1, Alessandro Palumbo1, Stefania Rossi1, Francesca Degobbis1, Stefano Cernic1, Giuseppe Tona2 and Maria Cova1

1 Department of Radiology, University of Trieste, Cattinara Hospital, Strada di Fiume 447, Trieste 34149, Italy.
2 Department of Radiology, Hospital of Mestre-Venice, Venice, Italy.

Received March 24, 2005; accepted after revision August 12, 2005.

 
Address correspondence to E. Quaia (equaia{at}yahoo.com).


Abstract
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
APPENDIX 1: Imaging Criteria...
References
 
OBJECTIVE. The objective of our study was to compare diagnostic performance of visual and quantitative analysis for the characterization of liver tumors insonated at low transmit power after microbubble contrast agent injection.

SUBJECTS AND METHODS. This series comprised 166 liver tumors (1-5 cm in diameter) in 166 patients (99 men, 67 women; mean age ± SD, 58 ± 11 years) scanned at low transmit power (mechanical index: 0.1-0.14) after sulfur hexafluoride-filled microbubble injection. Digital cine clips recorded at the arterial phase (10-40 sec after contrast injection) and late phase (100-300 sec) were analyzed to characterize liver tumors as benign or malignant. Visual analysis was performed by three independent blinded reviewers who evaluated enhancement patterns at the arterial phase and subjective tumor conspicuity at the late phase. Quantitative analysis of videotape intensity (VI: gray-scale levels, 0-255) was performed to calculate objective tumor conspicuity at the late phase: (VItumor - VIliver) / VIliver.

RESULTS. Characteristic enhancement patterns were observed in malignant tumors (peripheral rimlike) and benign tumors (peripheral nodular or central and spoke-wheel-shaped). Malignant (n = 95) versus benign (n = 71) tumors differed for subjective (median value: -1 vs 1, respectively) and objective conspicuity at the late phase (-0.6 vs 0.15, respectively; p = 0.001, Mann-Whitney U test) due to persistent microbubble uptake in benign tumors. Diagnostic performance of visual (odds ratio: reviewer 1 = 4.28, reviewer 2 = 10.18, reviewer 3 = 9.56) and quantitative (odds ratio: 89.33) analyses differed significantly in the characterization of liver tumors (p = 0.01, chi-square test).

CONCLUSION. Quantitative analysis revealed higher diagnostic performance than visual analysis to characterize liver tumors insonated at low transmit power after microbubble contrast agent injection.

Keywords: contrast media • harmonic sonography • insonation • liver • liver disease • sonography


Introduction
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
APPENDIX 1: Imaging Criteria...
References
 
Baseline gray-scale sonography and color Doppler sonography are limited in the characterization of liver tumors because of the similar appearance and vascular architecture of malignant and benign tumors [1, 2]. Microbubble contrast agents with dedicated contrast-specific modes have been shown to overcome the limitations of baseline sonography and to allow improved overall diagnostic performance [3-6].

Microbubbles present a small diameter ({approx} 3 µ), a shell of biologically inert material (galactose [e.g., Levovist, SH U 508A, Schering]; albumin [e.g., Optison, Amersham Health]; or phospholipids [e.g., Definity, Bristol-Myers Squibb]), and a different filling gas (air [e.g., Levovist]; perfluorocarbon [e.g., Definity]; or sulfur hexafluoride [SonoVue, Bracco-Italy]). High-transmit-power insonation (mechanical index = 0.9-1.2) produces bubbles destruction with emission of a wideband harmonic signal and presents several drawbacks such as the transiency of harmonic signals, the lack of suppression of background stationary tissues, and the strong presence of artifacts [6, 7]. Conversely, low-transmit-power insonation (mechanical index = 0.08-0.2) produces selective resonance of microbubbles with persistent harmonics emission and effective background suppression [7]. The vascularity of solid liver tumors is depicted at the arterial phase (10-40 sec from contrast injection) with enhancement patterns differing according to the tumor histotype [3-6, 8-12], while the malignant or benign nature of the tumor is defined at the late phase (100-300 sec from contrast injection) by evidence of persistent microbubble uptake in benign tumors and washout in malignant tumors [13-15].

Visual analysis is the first-line method to assess liver tumors after contrast injection, although it is limited by wide interobserver variability [5, 8, 10, 16] and depends on observer experience, with a consequent low reproducibility of results. Quantitative analysis is the second-line method, which provides more objective, reliable, and reproducible results [8, 16, 17]. Quantitation of sonography videotape intensity was previously shown to effectively characterize liver tumors after high-transmit-power insonation [13, 17], even though visual analysis and quantitative analysis were not compared. Moreover, because low-transmit-power insonation produces fewer artifacts than high transmit power [18], it is expected to allow an even more reliable quantitative analysis of sonography videotape intensity.

The aim of this study was to compare diagnostic performance of visual analysis with quantitative analysis for the characterization of liver tumors insonated at low transmit power after microbubble contrast agent injection.


Subjects and Methods
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
APPENDIX 1: Imaging Criteria...
References
 
Patients
During a period of 30 months, 636 consecutive patients were referred to our department for routine or surveillance sonography of the liver, which was performed by board-registered diagnostic radiologists with a similar amount of experience in sonography (10-15 years). In 256 patients, from one to three liver tumors were identified, 166 of whom were included in this study (Table 1). Inclusion criteria were at least one liver tumor considered indeterminate in consensus by the on-site radiologist and the supervising radiologist, who was responsible for the study and who had 10 years of experience in liver sonography at the time of the study. Indeterminate liver tumors were those that did not reveal any typical features about their nature (benign or malignant) or histotype on baseline gray-scale and color Doppler sonography. Both the supervising and on-site radiologists were aware of the patients' clinical history at the time of diagnosis, even though they did not know biopsy results or findings from other imaging techniques. Exclusion criteria were obvious cysts (n = 10); tumors with typical appearance on baseline grayscale and color Doppler sonography (n = 45), including liver hemangiomas and focal fatty changes (homogeneously hyperechoic with no peripheral or intratumoral vessels), and focal fatty sparing (hypoechoic in a bright liver, triangular shape, and subcapsular location) if identified in nonneoplastic and noncirrhotic patients; tumors smaller than 10 mm in diameter (n = 10) or larger than 5 cm (n = 13) for consistency in analysis; tumors poorly visualized on baseline sonography (n = 5); and absence of consensus between the supervising and on-site radiologists (n = 7).


View this table:
[in this window]
[in a new window]

 
TABLE 1: General Features of Different Histotypes

 

Contrast-Enhanced Sonography
From 1 to 28 days after identification, each liver tumor was examined on contrast-enhanced sonography by the supervising radiologist, who had 7 years of experience in contrast-enhanced sonography of the liver at the time of the study. Approval was obtained by the ethics review board of our hospital, and informed consent was obtained from all patients at the time of scanning after the nature of the procedure had been fully explained.

In this study, only one liver tumor was scanned in each patient. If more than one liver tumor was identified, the tumor considered indeterminate at baseline and with the best possible acoustic window for scanning was selected. A preliminary baseline grayscale sonography scan was obtained, and liver tumors were located by liver segment according to Bismuth [19] and Couinaud [20] classification systems. The tumor diameter was measured in the transverse and longitudinal planes, and the largest diameter in centimeters was registered (Table 1).

Each tumor was then examined after the injection of an IV bolus (2.4 mL in {approx} 2 sec) of sulfur hexafluoride-filled microbubbles (BR 1, SonoVue, Bracco) followed by a 2-mL flush of 0.9% NaCl. Sonography was performed while the patient was breathing normally or during breath-holding, depending on which yielded the best visualization of the tumor. For consistency in imaging technique and analysis, all sonography examinations were performed using the same system (HDI 5000 with C5-2 convex array probe, Advanced Technology Laboratories-Philips). The technical parameters were as follows: pulse inversion mode as the contrast-specific sonography technique, central transmit frequency of 3.5-3.7 MHz, low transmit power (mechanical index: 0.1-0.14), dynamic range of 65 dB, temporal resolution between frames of 75-100 msec (10-13 frames for seconds), echo-signal gain below noise visibility, signal persistence turned off, and one focus below the level of the tumor.

Uncompressed audio video interleaved (AVI) digital cine clips were recorded by a digital video camera (PC 105E, Sony) connected to the sonography equipment during the arterial (10-40 sec from contrast injection), portal (45-95 sec), and late (100-300 sec) phases and were successively stored in a PC (Intel, Pentium 4). Digital cine clips showed 10-20 sec during the arterial and portal phases and 60-80 sec during the late phase.


Figure 1
View larger version (17K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1A —Criteria for visual diagnosis of solid liver tumors after microbubble contrast agent injection. Higher, similar, or lower in echogenicity compared with adjacent liver was assessed, respectively, as hypervascular (subjective conspicuity = 1 or 2), isovascular (subjective conspicuity = 0), or hypovascular (subjective conspicuity = -2 or -1). Criteria used for visual diagnosis of malignancy: Diffuse indicates that enhancement of whole lesion was homogeneous or heterogeneous; peripheral rimlike, continuous ring of peripheral contrast enhancement; and absent, no difference before and after microbubble injection, with persistent hypovascular appearance.

 


Figure 2
View larger version (21K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1B —Criteria for visual diagnosis of solid liver tumors after microbubble contrast agent injection. Higher, similar, or lower in echogenicity compared with adjacent liver was assessed, respectively, as hypervascular (subjective conspicuity = 1 or 2), isovascular (subjective conspicuity = 0), or hypovascular (subjective conspicuity = -2 or -1). Criteria used for visual diagnosis of benignancy: Diffuse indicates that enhancement of whole lesion was homogeneous or heterogeneous; peripheral nodular, discontinuous or continuous peripheral enhancement with nodular appearance; central spoke-wheel-shaped, enhancing central vessel appeared to branch toward the periphery of the lesion; and absent, no difference before and after microbubble injection, with persistent hypovascular appearance.

 
Visual Analysis
From 1 to 3 days after contrast-enhanced sonography, digital cine clips were blindly reviewed by three off-site reviewers who were radiologists with 2, 5, and 7 years' experience in contrast-enhanced sonography of the liver and who had not been involved in the scanning. All reviews were performed on the same computer (Intel, Pentium 4 with 15-inch [38 cm] TFT [thin film transistor] display) at a central location. To simplify the procedure, we excluded the portal phase from analysis because the arterial and late phases have been proven to be the most important in characterizing liver tumors [3-6, 14-16].

The diagnostic criteria reported in Figures 1A and 1B were obtained from previous studies [3-6]. Each reviewer was presented with digital cine clips registered at the arterial and late phases and was asked to diagnose each tumor as benign or malignant on the basis of the enhancement patterns at the arterial phase and subjective tumor conspicuity at the late phase. In the assessment of tumor conspicuity, each reviewer compared the gray-scale intensity of the most enhancing portion of the tumor with the adjacent liver parenchyma according to a 5-grade system (Figs. 2A, 2B, 2C, 2D and 2E). For those enhancement patterns (e.g., diffuse homogeneous, diffuse heterogeneous, or absent) that are common for both malignant and benign tumors, tumor conspicuity at the late phase was considered determinant for differential diagnosis (hypovascular = malignant; isoto hypervascular = benign).


Figure 3
View larger version (116K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2A —Images show examples of 5-grade system used for visual analysis of conspicuity of liver tumors at late phase. 50-year-old woman with hepatocellular carcinoma (arrow). Score = 2: hypervascular tumor presenting gray-scale intensity at least double that of adjacent liver.

 

Figure 4
View larger version (153K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2B —Images show examples of 5-grade system used for visual analysis of conspicuity of liver tumors at late phase. 30-year-old woman with focal nodular hyperplasia (arrows). Score = 1: hypervascular tumor presenting gray-scale intensity slightly higher (less than double) than that of adjacent liver.

 

Figure 5
View larger version (148K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2C —Images show examples of 5-grade system used for visual analysis of conspicuity of liver tumors at late phase. 45-year-old woman with hepatocellular adenoma (arrows). Score = 0: isovascular tumor with gray-scale intensity equal to that of adjacent liver.

 

Figure 6
View larger version (184K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2D —Images show examples of 5-grade system used for visual analysis of conspicuity of liver tumors at late phase. 50-year-old woman with hepatocellular carcinoma (arrows). Score = -1: hypovascular tumor presenting gray-scale intensity slightly lower (less than half) than that of adjacent liver.

 

Figure 7
View larger version (141K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2E —Images show examples of 5-grade system used for visual analysis of conspicuity of liver tumors at late phase. 57-year-old woman with liver metastasis (arrows) from colon carcinoma. Score = -2: hypovascular tumor presenting gray-scale intensity at least half that of adjacent liver.

 
Quantitative Analysis
From 1 to 2 days after visual analysis, two observers—who were chief residents not involved in scanning, unaware of reference procedures results, and experienced in sonography and contrast-enhanced sonography of the liver, respectively, for 3 and 4 years—grabbed in consensus five frames from the cine clips recorded at the late phase using a proprietary software package (Mediacruise, Canopus). The selected frames, instead of the cine clips, were analyzed because liver motion caused variability in the scanning level; an effort was made to select frames acquired at the same level. The frames were separated by at least 5 sec, according to the lowest presence of artifacts and the best visibility of the tumor and adjacent liver parenchyma, and were stored as 8-bit (28 = 0-255 gray-scale levels) TIFF images, 768 x 576 pixels (pixel dimension: 0.2 mm), and black-and-white (gray-scale) mode.

The TIFF images were analyzed using software (Photoshop [release 7.0], Adobe Systems). In each image, two circular (range, 4,100-40,110 pixels; mean, 21,430 pixels) manually defined regions of interests (ROIs) were drawn in consensus by the two observers: The first encompassed the major portion of the tumor (Fig. 3A) and the second, a portion of the adjacent liver parenchyma with homogeneous appearance (Fig. 3B). Both ROIs were drawn at approximately the same depth, avoiding blood vessels, artifacts, and the echogenic walls of portal vessels.


Figure 8
View larger version (83K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 3A —70-year-old woman with macroregenerative nodule (arrow) in cirrhotic liver. Quantitative analysis of sonography videotape intensity in selected frames grabbed from digital cine clips recorded during arterial phase, 30 sec after microbubble contrast agent injection. Regions of interests (ROIs) are positioned in liver tumor, Corresponding histograms (insets) reveal distribution of sonography videotape intensity in gray-scale levels (0-255) in each ROI.

 

Figure 9
View larger version (84K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 3B —70-year-old woman with macroregenerative nodule (arrow) in cirrhotic liver. Quantitative analysis of sonography videotape intensity in selected frames grabbed from digital cine clips recorded during arterial phase, 30 sec after microbubble contrast agent injection. adjacent liver parenchyma. Corresponding histograms (insets) reveal distribution of sonography videotape intensity in gray-scale levels (0-255) in each ROI.

 


Figure 10
View larger version (86K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 3C —70-year-old woman with macroregenerative nodule (arrow) in cirrhotic liver. Quantitative analysis of sonography videotape intensity in selected frames grabbed from digital cine clips recorded during arterial phase, 30 sec after microbubble contrast agent injection. Another ROI is positioned outside picture to register sonography videotape intensity of background at constant level (35-40 gray-scale levels) in each analyzed frame. Objective conspicuity of tumor was -0.96.

 
The sonography videotape intensity was measured in gray-scale levels, from 0 (black pixels) to 255 (white pixels), through histogram analysis, expressing the mean ± SD video intensity of the pixels comprising each ROI. To set the background videotape intensity at the same level in each analyzed frame, another ROI (100-150 pixels; mean, 110 pixels) was positioned outside the picture where the gray-scale was maintained at 35-40 levels (Fig. 3C). The sonography videotape intensity (VI) was averaged, and the objective tumor conspicuity was calculated according to the following mathematic formula:

Formula

which we developed by also considering previous studies [13]. Objective tumor conspicuity was < 0 in tumors that were hypovascular compared with adjacent liver parenchyma and ≥ 0 in those that were isoor hypervascular. The predefined value of 0 was selected as the cutoff to differentiate benign from malignant tumors. This cutoff value was based on previous studies [3-5, 8-15] in which malignant tumors were described as mostly hypovascular compared with adjacent liver, whereas benign tumors revealed persistent microbubble uptake and appeared isoto hypervascular.


Figure 11
View larger version (127K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 4A —61-year-old man with hepatocellular carcinoma in cirrhotic liver. Diffuse heterogeneous contrast enhancement is seen in tumor (arrows) 30 sec after microbubble contrast agent injection.

 


Figure 12
View larger version (120K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 4B —61-year-old man with hepatocellular carcinoma in cirrhotic liver. Hypovascular appearance of tumor (arrows) 180 sec after contrast injection, which represents typical appearance of malignant tumor at late phase.

 


Figure 13
View larger version (130K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 5A —65-year-old man with liver hemangioma. Nodular peripheral enhancement (arrow) appears 25 sec after microbubble contrast agent injection.

 


Figure 14
View larger version (122K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 5B —65-year-old man with liver hemangioma. Progressive complete centripetal fill-in with hypervascular appearance (arrow) is revealed 220 sec after contrast injection, which represents typical appearance of benign tumor at late phase.

 
Reference Standards Procedures
From 10 days to 1 month after contrast-enhanced sonography, liver tumors were analyzed by reference standards procedures to obtain a definite diagnosis (Table 1). Histopathologic findings obtained from percutaneous sonographically guided core needle biopsy or surgical specimen were considered as the reference standards in 97 tumors, malignant (n =63) or benign (n = 34). The remaining 69 tumors were not biopsied for clinical reasons (e.g., high bleeding risk, patient refusal) or because of the high probability of hemangioma diagnosis; the diagnosis of malignancy (n = 32) or benignancy (n = 37) was made after multiphase contrast-enhanced CT or MRI (or both) based on established diagnostic criteria, which are described in Appendix 1. CT and MR images were interpreted by two senior radiologists in consensus who had 10-15 years' experience in liver imaging and who were blinded to the results of the other imaging techniques. In those cases in which contrast-enhanced CT or MR images were not conclusive for a malignant or benign nature, serial sonography examinations (n = 15) were performed at least 3-6 months apart with the aid of any relevant clinical information and considering an increase in lesion diameter or in the number of lesions as criteria for malignancy.


Figure 15
View larger version (6K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 6A —Scatterplots of subjective tumor conspicuity at late phase for different reviewers. Horizontal line indicates median values. Difference between malignant and benign liver tumors was found significant at late phase (p= 0.001, nonparametric Mann-Whitney U test). Scatterplots for reviewers 1.

 


Figure 16
View larger version (6K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 6B —Scatterplots of subjective tumor conspicuity at late phase for different reviewers. Horizontal line indicates median values. Difference between malignant and benign liver tumors was found significant at late phase (p= 0.001, nonparametric Mann-Whitney U test). Scatterplots for reviewers 2.

 


Figure 17
View larger version (6K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 6C —Scatterplots of subjective tumor conspicuity at late phase for different reviewers. Horizontal line indicates median values. Difference between malignant and benign liver tumors was found significant at late phase (p= 0.001, nonparametric Mann-Whitney U test). Scatterplots for reviewers 3.

 
Statistical Analysis
Statistical analysis was performed with a software package (Analyse-it [version 1.63] add-in for Excel, Microsoft Windows). The weighted kappa statistic was calculated to assess interobserver agreement. Agreement was graded as poor ({kappa} value < 0.20), moderate (≥ 0.20 and < 0.40), fair (≥ 0.40 and < 0.60), good (≥ 0.60 and < 0.80), or very good (≥ 0.8-1).

After the Shapiro-Wilk test failed to show evidence of normal distribution, the nonparametric Mann-Whitney U test was used to test the differences between malignant and benign tumors in subjective and objective conspicuity median values. The difference in diagnostic performance between visual and quantitative analysis was assessed through the chi-square test with Yates correction. A p value of less than 0.05 was considered to indicate significant difference.


Results
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
APPENDIX 1: Imaging Criteria...
References
 
Final Diagnoses
Finally, 95 malignant tumors (hepatocellular carcinomas, n = 49; metastases, n = 44; and cholangiocarcinomas, n = 2) and 71 benign tumors (hemangiomas, n = 37; macroregenerative nodules, n = 19; focal nodular hyperplasias, n = 9; and hepatocellular adenomas, n =6) were diagnosed (Table 1).

Visual Analysis
Enhancement patterns at the arterial phase— Hepatocellular carcinomas revealed diffuse homogeneous (n = 22) or heterogeneous (n = 27) contrast enhancement (Figs. 4A and 4B). Metastases revealed absent (n = 12), diffuse (n = 30), or rimlike (n = 2) enhancement. Peripheral cholangiocarcinomas displayed persistent absent enhancement with a hypovascular appearance.

Most liver hemangiomas (n = 32) revealed nodular peripheral enhancement with progressive centripetal fill-in (Figs. 5A and 5B). Diffuse contrast enhancement was identified in three liver hemangiomas < 3 cm that were proven to be hypervascular at histology, and absent contrast enhancement was observed in two liver hemangiomas < 3 cm that were proven to be thrombosed at histology. Most macroregenerative nodules (n = 14) revealed absent contrast enhancement, whereas diffuse contrast enhancement was observed in the remaining macroregenerative nodules with a dysplastic pattern (n = 5). Focal nodular hyperplasias revealed diffuse homogeneous contrast enhancement, preceded (n = 7) or not (n = 2) by central-spoke-wheel-shaped enhancement lasting for 2-5 sec. Hepatocellular adenomas revealed persistent diffuse heterogeneous contrast enhancement.

Subjective tumor conspicuity at the late phase—Distribution of subjective tumor conspicuity values at the late phase for each reviewer is shown in Figures 6A, 6B and 6C. Malignant tumors appeared prevalently hypovascular (median subjective conspicuity = -1 for all reviewers), whereas benign tumors appeared prevalently hypervascular (median subjective conspicuity = 1 for all reviewers). The difference in subjective conspicuity grading was significant (p = 0.001) with good interobserver agreement ({kappa} = 0.73, reviewer 1 vs reviewer 2; 0.76, reviewer 2 vs 3; 0.77, reviewer 1 vs 3).

Quantitative Analysis: Objective Tumor Conspicuity at the Late Phase
The distribution of objective tumor conspicuity values at the late phase for the different histotypes is shown in Table 2, and the distribution of objective tumor conspicuity values for benign and malignant tumors is shown in Figure 7.


View this table:
[in this window]
[in a new window]

 
TABLE 2: Objective Tumor Conspicuity Values at Late Phase

 

Figure 18
View larger version (10K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 7 —Scatterplots of objective tumor conspicuity at late phase. Horizontal lines indicate median values. Difference between malignant and benign liver tumors was found significant at late phase (p= 0.001, nonparametric Mann-Whitney U test). If compared with subjective analysis, quantitative analysis allowed less overlap between conspicuity values of malignant and benign tumors.

 

According to the tumor nature, objective conspicuity was < 0 in 80 (84%) of 95 malignant tumors and ≥ 0 in 67 (94%) of 71 benign tumors, and the difference in the median values was significant (p = 0.001). Objective conspicuity was ≥ 0 in 15 (16%) of 95 malignant tumors, while it was < 0 in four (6%) of 71 benign tumors.

According to the tumor histotypes, 15 (31%) of 49 well-differentiated (n = 10) or moderately-poorly differentiated (n = 5) hepatocellular carcinomas revealed objective conspicuity of ≥ 0, while two (40%) of five dysplastic nodules with high (n = 1) or low (n = 1) grade and two (5%) of 37 hemangiomas with a thrombotic pattern revealed objective conspicuity of < 0. Intrahepatic cholangiocarcinomas revealed conspicuity of < 0, similarly to the other malignant histotypes.

Comparison of Visual Versus Quantitative Analysis in Diagnostic Performance
Results of diagnostic performance of visual analysis and quantitative analysis are shown in Table 3. The difference in diagnostic performance between the different reviewers was not significant (p 0.05), and the interobserver agreement was very good ({kappa} = 0.86, reviewer 1 vs reviewer 2; 0.81, reviewer 2 vs 3; 0.88, reviewer 1 vs 3).


View this table:
[in this window]
[in a new window]

 
TABLE 3: Values of Diagnostic Performance for Visual and Quantitative Analyses

 

The diagnostic performance of visual analysis and quantitative analysis differed significantly (p = 0.01) because quantitative analysis improved the characterization of the tumors that presented equivocal subjective conspicuity at the late phase for the reviewers (e.g., -1 for reviewer 1 and 0 for reviewers 2 and 3) and consequently were incorrectly characterized as benign or malignant at visual analysis. Quantitative analysis changed the initial diagnosis proposed after visual analysis in 34 cases (16 hepatocellular carcinomas, two metastases, two hemangiomas, 12 macroregenerative nodules, and two hepatocellular adenomas) for reviewer 1, in 20 cases (12 hepatocellular carcinomas, one hemangioma, five macroregenerative nodules, and two hepatocellular adenomas) for reviewer 2, and in 21 cases (15 hepatocellular carcinomas, four macroregenerative nodules, and two hepatocellular adenomas) for reviewer 3.


Discussion
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
APPENDIX 1: Imaging Criteria...
References
 
Dedicated contrast-specific modes with microbubble contrast agents were previously shown to improve the overall diagnostic performance in the characterization of liver tumors compared with baseline sonography [3-6]. Microbubble-based contrast agents are gas bubbles with a small diameter ({approx} 3 µ) that are filled by air or gas with low solubility in the blood and covered by a shell of biologically inert material (albumin or phospholipids).

SonoVue is a sulfur hexafluoride-filled microbubble contrast agent consisting of bubbles encapsulated by a flexible shell of phospholipids. According to the procedure suggested by the pharmaceutical company (Bracco), a white suspension of microbubble is obtained from 25 mg of lyophilisate powder by adding 5 mL of physiologic saline to the powder, followed by hand agitation [7, 21, 22]. The obtained microbubbles present a density of 2 x 108 microbubbles per milliliter and a mean diameter of 3 µ (90% of microbubbles < 8 µ) and are stable in the vial for a few hours (< 6 hr). Although not yet allowed for use in the United States, sulfur hexafluoride-filled microbubbles are licensed in most European countries for abdominal and vascular imaging and present a strong nonlinear harmonic response when insonated by low transmit power [7, 21, 22].

High transmit power is used after air-filled microbubble (e.g., Levovist) injection because the galactose shell of air-filled microbubbles presents very low harmonic behavior [7] and the only way to produce harmonics is to cause extensive bubble destruction with the emission of a wideband signal. On the other hand, low transmit power is used to insonate perfluorocarbon or sulfur hexafluoride-filled microbubbles. Low-transmit-power insonation causes the selective resonance of microbubbles with harmonics emission and the effective suppression of the background signal from stationary tissues [18]. Low-transmit-power insonation allows continuous scanning with the possibility to assess the tumor contrast enhancement in real time, even though a lower signal is produced in comparison with high-transmit-power insonation [18].

After contrast administration, visual analysis is the simplest method by which to assess liver tumors, despite the disadvantages of interobserver variability and low reproducibility of results [5, 16]. Quantitative analysis of sonography videotape intensity is more complex, although it is expected to provide more objective, reliable, and reproducible results [13, 17].

In this study, visual analysis and quantitative analysis were compared in characterizing liver tumors. As previously shown [3-6, 8-15], different enhancement patterns were observed in malignant tumors (rimlike in metastases) and benign tumors (peripheral nodular in hemangiomas and spoke-wheel-shaped in focal nodular hyperplasia) after microbubble contrast agent injection. Malignant and benign liver tumors also revealed common enhancement patterns (diffuse heterogeneous in both hepatocellular carcinomas and hepatocellular adenomas; diffuse homogeneous in both hepatocellular carcinomas and fibrous nodular hyperplasias; absent enhancement in both metastases and avascular thrombotic liver hemangiomas). For these reasons, enhancement patterns are not sufficient for characterizing liver tumors, and the analysis of the appearance of the liver tumors at the late phase is fundamental because malignant tumors prevalently showed microbubbles washout, whereas benign tumors prevalently showed a persistent microbubble uptake [13-15].

Diagnostic performance of visual analysis revealed very good interobserver agreement, even though observers present with different levels of experience with contrast-enhanced sonography. This result is explained by the characteristic contrast enhancement patterns observed in most examined tumors [3-6]. The residual interobserver variability in diagnostic performance was determined by the larger interobserver variability in the assessment of subjective tumor conspicuity at the late phase.

Quantitative analysis allowed improvement of the overall diagnostic performance compared with visual analysis due to more accurate assessment of tumor conspicuity at the late phase. This is probably because visual analysis is often penalized by the fact that the eyes of observers usually focus on a particular portion of the lesion, whereas quantitative analysis allows comparison of the echogenicity of the tumor and of the adjacent liver in a more global and reproducible manner. Quantitative analysis also allows the polarity of conspicuity—from hypovascular to isovascular or from isovascular to hypovascular—to be changed in many tumors with a consequent correction of the diagnosis proposed after visual analysis. This is also emphasized by the lower overlap between conspicuity data of malignant and of benign tumors in quantitative analysis compared with visual analysis.

In this study, a mathematic formula was proposed to calculate objective contrast-enhanced tumor conspicuity from gray-scale images obtained using the pulse inversion mode. This formula is original, even though a similar formula was developed and used in previous studies [13] in which tumor conspicuity was quantified after insonation by stimulated acoustic emission, which is a color Doppler contrast-specific mode.

Quantitative analysis of sonography videotape intensity depends on the several stages of postprocessing performed in sonography equipment for image videotape presentation, including log compression, that modify the original features of the signal. Numerous other factors may affect the gray-scale appearance of tumors and normal livers, such as tumor depth and signal absorption; the pre- and postprocessing settings on the sonography scanner, such as echo-signal gain, grayscale mapping, transmit power, and frame rate [23]; the microbubbles injection rate, volume, and concentration; and scanning delay time [24, 25]. These limitations are always present in the quantitative analysis of sonography videotape intensity [13, 17] and in this study were reduced by using one sonography unit and normalizing the gray-scale intensity measured in liver tumors to that measured in the adjacent liver.

Objective tumor conspicuity of 0 at the late phase—equal intensity of the tumor and liver after contrast injection—was selected as the cutoff to differentiate malignant from benign liver tumors because microbubbles washout was previously described as prevalent in malignant lesions, whereas persistent microbubbles uptake has been described in benign lesions [3-5, 8-15]. Our study confirmed those results, even though sulfur hexafluoride-filled microbubbles do not present a late liver-specific phase as air-filled microbubbles do, probably because of the different shell composition with a lower affinity for liver sinusoids [26]. The persistent bubble uptake in benign lesions observed in the present study was probably determined by the similar vascular network in terms of vessels structure and flow velocity in tumors and adjacent liver—for example, in focal nodular hyperplasia—or by the persistent microbubbles pooling in vessels with slow flow—for example, in hemangiomas. The different vascular architecture compared with adjacent liver probably determined microbubbles washout at the late phase in malignant tumors.

A clear overlap between benign and malignant tumors persists even after quantitative analysis because some liver tumors are prevalent in patients with chronic liver disease or cirrhosis (or both). In the present study, 30% of the hepatocellular carcinomas revealed a conspicuity of ≥ 0 at the late phase, which is similar to benign tumors. This finding confirms those of previous studies [5, 11] in which the percentage of isoto hypervascular hepatocellular carcinomas at the late phase was reported to range from 33% to 38%, and it was determined by the variable grade of microbubbles uptake in different hepatocellular carcinomas, which correlates with the grade of tumor differentiation [27, 28], or by the absence of liver-specific uptake for sulfur hexafluoride-filled microbubbles [6, 7, 12].

On the other hand, some low- or high-grade dysplastic macroregenerative nodules revealed an objective conspicuity of < 0 as for malignant tumors. The atypical conspicuity of these tumors at the late phase resulted in an incorrect diagnosis even after quantitative analysis. According to these findings, any tumor identified in a patient with chronic liver disease or cirrhosis should be analyzed with high suspicion. Each tumor with a hypovascular appearance at the late phase after microbubble contrast agent injection must be considered malignant in both the normal and the cirrhotic liver [5, 29, 30]. Moreover, besides tumor conspicuity, tumor appearance at the arterial phase is fundamental in patients with chronic liver disease because malignant tumors—namely, hepatocellular carcinomas—appear prevalently hypervascular, whereas benign tumors—namely, macroregenerative nodules and hemangiomas—appear prevalently hypoor isovascular [29, 30]. However, distinction between dysplastic macroregenerative nodules and hypovascular well-differentiated hepatocellular carcinomas remains difficult both by imaging techniques and at histology [31].

Besides tumors in patients with chronic liver disease, thrombotic liver hemangiomas showed an atypical appearance at the late phase with a conspicuity of < 0 and a hypovascular appearance. This finding was determined by the absence of persistent microbubbles uptake in thrombotic avascular tumors. Intrahepatic cholangiocarcinoma appeared hypovascular to the adjacent liver at the late phase, similar to the other malignant tumors. This tumor may retain contrast material on delayed contrast-enhanced CT or MR images because contrast material in the interstitial spaces of the tumor diffuses slowly [32]. The appearance of cholangiocarcinoma on contrast-enhanced sonography was due to the peculiar properties of microbubble contrast agents, which do not leak in the fibrous stroma [7] and determine the persistent hypovascular appearance of tumor.

The first limitation of this study was the fact that a single liver tumor was assessed on contrast-enhanced sonography because the transducer must remain still during scanning. This protocol was selected for consistency in the comparison of visual analysis and quantitative analysis because the assessment of more tumors in the same patients could make this comparison difficult. In practice, additional microbubble injections would be necessary to characterize adjunctive liver tumors, and this factor also must be considered a disadvantage in comparison with multiphasic CT and MRI, which allow simultaneous characterization of multiple liver tumors of similar or different nature in the same patient.

The second limitation was the lack of histologic correlation in slightly more than one third of the tumors. All liver tumors that were not examined at histology were characterized by strictly established diagnostic criteria consisting of typical contrast enhancement patterns observed on multiphase contrast-enhanced CT or MRI. Lesions with an atypical appearance or incompletely characterized on CT or MRI were all biopsied or were surgically removed for histologic analysis.

In conclusion, quantitative analysis revealed higher diagnostic performance than visual analysis for the characterization of liver tumors insonated at low transmit power after microbubble contrast agent injection.


APPENDIX 1: Imaging Criteria for the Diagnosis of 69 Tumors That Were Not Biopsied for Clinical Reasons or Because of the High Probability of Hemangioma
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
APPENDIX 1: Imaging Criteria...
References
 
Criteria for diagnosis of
Hepatocellular carcinoma

Metastasis

Hemangioma

Focal nodular hyperplasia

Intrahepatic cholangiocarcinomas, macroregenerative nodules, and hepatocellular adenomas
• Histology result


References
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
APPENDIX 1: Imaging Criteria...
References
 

  1. Nino-Murcia M, Ralls PW, Jeffrey RB Jr, Johnson M. Color flow Doppler characterization of focal hepatic lesions. AJR1992; 159:1195 -1197[Abstract/Free Full Text]
  2. Harvey CJ, Albrecht T. Ultrasound of focal liver lesions. Eur Radiol 2001;11 : 1578-1593[CrossRef][Medline]
  3. Kim TK, Choi BI, Han JK, Hong HS, Park SH, Moon SG. Hepatic tumours: contrast agent-enhancement patterns with pulse inversion harmonic US. Radiology 2000;216 : 411-417[Abstract/Free Full Text]
  4. Tanaka S, Ioka T, Oshikawa O, Hamada Y, Yoshioka F. Dynamic sonography of hepatic tumors. AJR 2001;177 : 799-805[Abstract/Free Full Text]
  5. Quaia E, Calliada F, Bertolotto M, et al. Characterization of focal liver lesions by contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology 2004;232 : 420-430[Abstract/Free Full Text]
  6. Cosgrove D, Blomley M. Liver tumors: evaluation with contrast-enhanced ultrasound. Abdom Imaging2004; 29:446 -454[Medline]
  7. Quaia E. Classification and safety of microbubble-based contrast agents. In: Quaia E, ed. Contrast media in ultrasonography: basic principles and clinical applications. Berlin, Germany: Springer,2005 : 3-14
  8. Wen YL, Kudo M, Zheng RQ, et al. Characterization of hepatic tumors: value of contrast-enhanced coded phase-inversion harmonic angio. AJR 2004; 182:1019 -1026 [erratum in[Abstract/Free Full Text]AJR 2004;183 : 1175][Free Full Text]
  9. Wilson SR, Burns PN, Murdali D, Wilson J, Lai X. Harmonic hepatic ultrasound with microbubble contrast agent: initial experience showing improved characterization of hemangioma, hepatocellular carcinoma and metastasis. Radiology 2000;215 : 153-161[Abstract/Free Full Text]
  10. Dill-Macky M, Burns P, Khalili K, Wilson S. Focal hepatic masses: enhancement patterns with SH U 508A and pulse inversion US. Radiology 2002;222 : 95-102[Abstract/Free Full Text]
  11. Isozaki T, Numata K, Kiba T, et al. Differential diagnosis of hepatic tumors by using contrast enhancement patterns at US. Radiology 2003;229 : 798-805[Abstract/Free Full Text]
  12. Quaia E, Bertolotto M, Calderan L, Mosconi E, Pozzi Mucelli R. US characterization of focal hepatic lesions with intermittent high acoustic power mode and contrast material. Acad Radiol2003; 10:739 -750[CrossRef][Medline]
  13. Blomley MJK, Sidhu PL, Cosgrove DO, et al. Do different types of liver lesions differ in their uptake of the microbubble contrast agent SH U 508A in the late liver phase? Early experience. Radiology 2001;220 : 661-667[Abstract/Free Full Text]
  14. von Herbay A, Vogt C, Haussinger D. Late-phase pulse-inversion sonography using the contrast agent Levovist: differentiation between benign and malignant focal lesions of the liver. AJR2002; 179:1273 -1279[Abstract/Free Full Text]
  15. Bryant T, Blomley MJK, Albrecht T, et al. Improved characterization of liver lesions with liver-phase uptake of liver specific microbubbles: prospective multicenter trials. Radiology2004; 232:799 -809[Abstract/Free Full Text]
  16. Kundel HL, Polansky M. Measurement of observer agreement. Radiology 2003;228 : 303-308[Abstract/Free Full Text]
  17. Klein D, Jenett M, Gassel HJ, Sandstede J, Hahn D. Quantitative dynamic contrast sonography of hepatic tumours. Eur Radiol 2004; 14:1082 -1091[Medline]
  18. Whittingham T. Contrast-specific imaging techniques: technical perspective. In: Quaia E, ed. Contrast media in ultrasonography: basic principles and clinical applications. Berlin, Germany: Springer, 2005: 43-70
  19. Bismuth H. Surgical anatomy and anatomical surgery of the liver. World J Surg 1982;6 : 3-8[CrossRef][Medline]
  20. Couinaud C. Le foie: etudes anatomiques et chirurgicales. Paris, France: Masson, 1957:9 -12
  21. Schneider M, Arditi M, Barrau MB, et al. BR1: a new ultrasonographic contrast agent based on sulphur hexafluoride-filled microbubbles. Invest Radiol 1995;30 : 451-457[Medline]
  22. Morel DR, Schwieger I, Hohn L, et al. Human pharmacokinetics and safety evaluation of SonoVue: a new contrast agent for ultrasound imaging. Invest Radiol 2000;35 : 80-85[CrossRef][Medline]
  23. Sirlin CB, Girard MS, Baker KG, Steinbach GC, Deiranieh LH, Mattrey RF. Effect of acquisition rate on liver and portal vein enhancement with microbubble contrast. Ultrasound Med Biol1999; 25:331 -338[CrossRef][Medline]
  24. Albrecht T, Urbank A, Mahler M, et al. Prolongation and optimization of Doppler enhancement with a microbubble US contrast agent by using continuous infusion: preliminary experience. Radiology 1998;207 : 339-347[Abstract/Free Full Text]
  25. Correas JM, Burns PN, Lai X, Qi X. Infusion versus bolus of an ultrasound contrast agent: in vivo dose-response measurements of BR1. Invest Radiol 2000;35 : 72-79[CrossRef][Medline]
  26. Blomley MJK, Albrecht T, Cosgrove DO, et al. Stimulated acoustic emission in liver parenchyma with Levovist. Lancet1998; 351:568 -569[Medline]
  27. Nicolau C, Català V, Vilana R, et al. Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation. Eur Radiol 2004; 14:1092 -1099[CrossRef][Medline]
  28. Koda M, Matsunaga Y, Ueki M, et al. Qualitative assessment of tumor vascularity in hepatocellular carcinoma by contrast-enhanced coded ultrasound: comparison with arterial phase of dynamic CT and conventional color/power Doppler ultrasound. Eur Radiol 2004;14 : 1100-1108[CrossRef][Medline]
  29. Lim JH, Cho JM, Kim EY, Park CK. Dysplastic nodules in liver cirrhosis: evaluation of hemodynamics with CT during arterial portography and CT hepatic arteriography. Radiology 2000;214 : 869-874[Abstract/Free Full Text]
  30. Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 2002;225 : 143-149[Abstract/Free Full Text]
  31. Longchampt E, Patriarche C, Fabre M. Accuracy of cytology vs microbiopsy for the diagnosis of well-differentiated hepatocellular carcinoma and macroregenerative nodule: definition of standardized criteria from a study of 100 cases. Acta Cytol 2000;44 : 515-523[Medline]
  32. Lacomis JM, Baron RL, Oliver JH, et al. Cholangiocarcinoma: delayed CT contrast enhancement patterns. Radiology1997; 203:98 -104[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J Ultrasound MedHome page
S. R. Wilson, H.-J. Jang, T. K. Kim, and P. N. Burns
Diagnosis of Focal Liver Masses on Ultrasonography: Comparison of Unenhanced and Contrast-Enhanced Scans
J. Ultrasound Med., June 1, 2007; 26(6): 775 - 787.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal